DE69030189D1 - Hemmung des wachstums von tumoren durch blockade des protein-c-systems - Google Patents

Hemmung des wachstums von tumoren durch blockade des protein-c-systems

Info

Publication number
DE69030189D1
DE69030189D1 DE69030189T DE69030189T DE69030189D1 DE 69030189 D1 DE69030189 D1 DE 69030189D1 DE 69030189 T DE69030189 T DE 69030189T DE 69030189 T DE69030189 T DE 69030189T DE 69030189 D1 DE69030189 D1 DE 69030189D1
Authority
DE
Germany
Prior art keywords
protein
blocking
inhibition
tumor growth
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69030189T
Other languages
English (en)
Other versions
DE69030189T2 (de
Inventor
Charles Esmon
Philip Comp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of DE69030189D1 publication Critical patent/DE69030189D1/de
Application granted granted Critical
Publication of DE69030189T2 publication Critical patent/DE69030189T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
DE69030189T 1989-08-04 1990-08-02 Hemmung des wachstums von tumoren durch blockade des protein-c-systems Expired - Fee Related DE69030189T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/389,617 US5147638A (en) 1988-12-30 1989-08-04 Inhibition of tumor growth by blockade of the protein C system
PCT/US1990/004337 WO1991001753A1 (en) 1989-08-04 1990-08-02 Inhibition of tumor growth by blockade of the protein c system

Publications (2)

Publication Number Publication Date
DE69030189D1 true DE69030189D1 (de) 1997-04-17
DE69030189T2 DE69030189T2 (de) 1997-07-10

Family

ID=23539002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69030189T Expired - Fee Related DE69030189T2 (de) 1989-08-04 1990-08-02 Hemmung des wachstums von tumoren durch blockade des protein-c-systems

Country Status (8)

Country Link
US (1) US5147638A (de)
EP (1) EP0489048B1 (de)
JP (1) JPH0729937B2 (de)
AT (1) ATE149842T1 (de)
AU (1) AU639014B2 (de)
CA (1) CA2064585C (de)
DE (1) DE69030189T2 (de)
WO (1) WO1991001753A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322838A (en) * 1988-11-16 1994-06-21 Brigham & Women's Hospital Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
EP0962529A1 (de) * 1991-10-23 1999-12-08 Thomas Jefferson University Synthese von humanen Prokollagenen und Kollagenen in rekombinanten DNA-Systemen
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP0651655A4 (de) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
EP0728210B1 (de) * 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutanten
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
WO1995034652A1 (en) * 1994-06-10 1995-12-21 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
US5695993A (en) * 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US6013483A (en) 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
CN100333796C (zh) 1997-01-22 2007-08-29 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子及其组合物
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
KR100794454B1 (ko) 1997-04-07 2008-01-16 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
ATE300957T1 (de) 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US20030077603A1 (en) * 1999-08-18 2003-04-24 Parekh Rajesh Bhikhu Methods and compositions for diagnosis of hepatoma
GB9919597D0 (en) * 1999-08-18 1999-10-20 Oxford Glycosciences Uk Ltd Methods and compositions for diagnosis of hepatoma
WO2001037873A2 (en) 1999-11-10 2001-05-31 Lentz M Rigdon Method and system to remove cytokine inhibitor in patients
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
CA2709771A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20020168360A1 (en) * 2001-03-02 2002-11-14 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
JP2005510516A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｓ阻害剤を含む薬学的組成物
EP1499352A4 (de) 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
US20040018197A1 (en) * 2002-04-26 2004-01-29 Promega Corporation Treatment for weight loss
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
EP1586328B1 (de) * 2002-12-27 2013-02-20 The Chemo-Sero-Therapeutic Research Institute Wirkstoff zur erhöhung der lebenserwartung bei der therapie bösartiger tumore
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
BRPI0409936A (pt) 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
WO2005014028A1 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
RU2378016C2 (ru) * 2004-04-30 2010-01-10 Байофересиз Текнолоджиз, Инк. Способ и система для удаления у пациентов растворимых tnfr1, tnfr2 и il2
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
EP2851064A3 (de) 2006-07-11 2015-08-05 Roy C. Levitt Prävention und Therapie von Rhinosinusitis mit proinflammatorischen Zytokinhemmern
JP2010500360A (ja) 2006-08-10 2010-01-07 アルボア コーポレーション 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7826800B2 (en) * 2006-11-27 2010-11-02 Orthosoft Inc. Method and system for determining a time delay between transmission and reception of an RF signal in a noisy RF environment using phase detection
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP2068925A4 (de) 2007-05-07 2011-08-31 Medimmune Llc Anti-icos-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
BRPI0905660A2 (pt) 2008-01-14 2015-07-07 Genentech Inc "método para reduzir ou inibir a angiogênese"
EP3858854A1 (de) 2008-06-25 2021-08-04 Novartis AG Stabile und lösliche tnf-inhibierende antikörper
KR101671886B1 (ko) 2008-06-25 2016-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
ES2870983T3 (es) 2014-12-19 2021-10-28 Univ Nantes Anticuerpos anti-IL-34
CA3114179A1 (en) 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
EP3889183A1 (de) 2020-04-01 2021-10-06 Pierre Fabre Medicament Proteinkomplex mit einem immunzytokin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3705745A1 (de) * 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
JP2634218B2 (ja) * 1987-03-02 1997-07-23 森永乳業株式会社 Ａｄｃｃ療法を高める組成物

Also Published As

Publication number Publication date
EP0489048A1 (de) 1992-06-10
CA2064585C (en) 1999-04-27
JPH0729937B2 (ja) 1995-04-05
DE69030189T2 (de) 1997-07-10
AU6164390A (en) 1991-03-11
JPH04504264A (ja) 1992-07-30
EP0489048B1 (de) 1997-03-12
CA2064585A1 (en) 1991-02-05
ATE149842T1 (de) 1997-03-15
US5147638A (en) 1992-09-15
AU639014B2 (en) 1993-07-15
WO1991001753A1 (en) 1991-02-21

Similar Documents

Publication Publication Date Title
ATE149842T1 (de) Hemmung des wachstums von tumoren durch blockade des protein-c-systems
Wallach et al. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1.
US5702697A (en) Treatment for biological damage using a colony stimulating factor and a biological modifier
US4985241A (en) Therapeutic combination of free-radical scavenger and tumor necrosis factor
NO852673L (no) Tumor-nekrosefaktor.
NO930893L (no) Ultralydformidlet administrering av forbindelser i akvatiske dyr
ATE186641T1 (de) Cytokinhemmer
ATE76579T1 (de) Interferon-zusammensetzungen.
Fox et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double-blind study
Sheppard et al. Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor
FI950144A (fi) Lysotsyymidimeeri ja sitä sisältävät koostumukset
PT99123A (pt) Processo para a preparacao de uma composicao farmaceutica contendo o factor de necrose de tumor e interleuquina-4
DE69025337D1 (de) Tumor-nekrose-faktor-antagonist
Quinn et al. Interleukin-2-induced lymphocyte infiltration of multiple organs is differentially suppressed by soluble tumor necrosis factor receptor
KR900700156A (ko) 개선된 방사선 치료법
RU95119067A (ru) Способ стимуляции половой функции крупного рогатого скота
Tamura et al. Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors
Currier et al. TNF-α further augments natural killer cells when co-administered with an interferon inducer to irradiated, leukemic, bone-marrow-transplanted mice
ATE373503T1 (de) Tumornekrosefaktor in kombination mit interferon in demyelinierungskrankheiten
Damais et al. Effect of rat recombinant interferon-γ and human recombinant interleukin-2 on chemiluminescence of peritoneal cells after ip injection to normal mice (Balb/c and MRL-+/+)
Jupin et al. Production of tumor necrosis factors and interferon-γ by human blood mononuclear cells stimulated by a staphylococcal toxin
Yonehara et al. A cell-killing monoclonal antibody for an antigen co-down-regulated with the TNF receptor
RU94022334A (ru) Способ лечения и профилактики инвазионных заболеваний
JPS63190831A (ja) 遊離基捕捉剤又は代謝抑制剤と生物活性蛋白質とを含有する医薬組成物
RU95104980A (ru) Производные бензола, способы их получения, фармацевтические композиции, содержащие их и способы лечения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee